Panitumumab Pivotal Study Shows Increase In Progression-Free Survival
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen/Abgenix say twelve-month survival data will be released by second quarter. Rolling BLA submission will begin by year-end, wrapping up in early 2006.